Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT; the SPIRIT-PRO Group, Hunn A, Bottomley A, Regnault A, Chan AW, Ells C, O'Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T.

JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.

PMID:
29411037
2.

Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells.

Lecendreux M, Churlaud G, Pitoiset F, Regnault A, Tran TA, Liblau R, Klatzmann D, Rosenzwajg M.

PLoS One. 2017 Jan 20;12(1):e0169836. doi: 10.1371/journal.pone.0169836. eCollection 2017.

3.

Towards the use of mixed methods inquiry as best practice in health outcomes research.

Regnault A, Willgoss T, Barbic S; International Society for Quality of Life Research (ISOQOL) Mixed Methods Special Interest Group (SIG).

J Patient Rep Outcomes. 2017;2(1):19. doi: 10.1186/s41687-018-0043-8. Epub 2018 Apr 11.

4.

Assessing the impact on caregivers of patients with schizophrenia: psychometric validation of the Schizophrenia Caregiver Questionnaire (SCQ).

Rofail D, Regnault A, le Scouiller S, Lambert J, Zarit SH.

BMC Psychiatry. 2016 Jul 18;16:245. doi: 10.1186/s12888-016-0951-1.

5.

Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.

Chowdary P, Kearney S, Regnault A, Hoxer CS, Yee DL.

Haemophilia. 2016 Jul;22(4):e267-74. doi: 10.1111/hae.12995. Epub 2016 Jun 28.

PMID:
27352908
6.

The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Robinson D Jr, Esseltine DL, Regnault A, Meunier J, Liu K, van de Velde H.

Br J Haematol. 2016 Aug;174(3):368-81. doi: 10.1111/bjh.14058. Epub 2016 Jun 5.

7.

Patient-reported outcomes in drug development for hematology.

Acquadro C, Regnault A.

Hematology Am Soc Hematol Educ Program. 2015;2015:496-500. doi: 10.1182/asheducation-2015.1.496.

PMID:
26637764
8.

Pro Claims in Fibromyalgia: A Review of the Labels of Products Approved by the Fda and the Ema.

Acquadro C, Perret C, Regnault A.

Value Health. 2015 Nov;18(7):A653. doi: 10.1016/j.jval.2015.09.2353. Epub 2015 Oct 20. No abstract available.

9.

Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin.

Rofail D, Regnault A, le Scouiller S, Berardo CG, Umbricht D, Fitzpatrick R.

Qual Life Res. 2016 Jan;25(1):201-11. doi: 10.1007/s11136-015-1057-9. Epub 2015 Jul 5.

PMID:
26143058
10.

Assessment of the impact of phenylketonuria and its treatment on quality of life of patients and parents from seven European countries.

Bosch AM, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Koledova E, Benmedjahed K, Regnault A.

Orphanet J Rare Dis. 2015 Jun 18;10:80. doi: 10.1186/s13023-015-0294-x.

11.

Cross-cultural adaptation of the Schizophrenia Caregiver Questionnaire (SCQ) and the Caregiver Global Impression (CaGI) Scales in 11 languages.

Rofail D, Acquadro C, Izquierdo C, Regnault A, Zarit SH.

Health Qual Life Outcomes. 2015 Jun 9;13:76. doi: 10.1186/s12955-015-0264-y.

12.

Development and psychometric validation of measures to assess the impact of phenylketonuria and its dietary treatment on patients' and parents' quality of life: the phenylketonuria - quality of life (PKU-QOL) questionnaires.

Regnault A, Burlina A, Cunningham A, Bettiol E, Moreau-Stucker F, Benmedjahed K, Bosch AM.

Orphanet J Rare Dis. 2015 May 10;10:59. doi: 10.1186/s13023-015-0261-6.

13.

Impact of cytokine in type 1 narcolepsy: Role of pandemic H1N1 vaccination ?

Lecendreux M, Libri V, Jaussent I, Mottez E, Lopez R, Lavault S, Regnault A, Arnulf I, Dauvilliers Y.

J Autoimmun. 2015 Jun;60:20-31. doi: 10.1016/j.jaut.2015.03.003. Epub 2015 Apr 16.

PMID:
25892508
14.

Impact of severe haemophilia A on patients' health status: results from the guardian(™) 1 clinical trial of turoctocog alfa (NovoEight(®) ).

Ozelo M, Chowdary P, Regnault A, Busk AK.

Haemophilia. 2015 Jul;21(4):451-7. doi: 10.1111/hae.12617. Epub 2015 Feb 12.

PMID:
25677761
15.

Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures.

Anthoine E, Moret L, Regnault A, Sébille V, Hardouin JB.

Health Qual Life Outcomes. 2014 Dec 9;12:176. doi: 10.1186/s12955-014-0176-2. Review.

16.

The "psychomicrobiotic": Targeting microbiota in major psychiatric disorders: A systematic review.

Fond G, Boukouaci W, Chevalier G, Regnault A, Eberl G, Hamdani N, Dickerson F, Macgregor A, Boyer L, Dargel A, Oliveira J, Tamouza R, Leboyer M.

Pathol Biol (Paris). 2015 Feb;63(1):35-42. doi: 10.1016/j.patbio.2014.10.003. Epub 2014 Nov 2. Review.

PMID:
25468489
17.

Psychometric Validation of the Newly Developed Phenylketonuria- Quality of Life (Pku-Qol) Questionnaires Assessing the Impact of Phenylketonuria and Its Treatment On Patients' Quality of Life.

Bosch AM, Burlina A, Cunningham A, Bettiol EO, Moreau-Stucker F, Benmedjahed K, Regnault A.

Value Health. 2014 Nov;17(7):A536. doi: 10.1016/j.jval.2014.08.1715. Epub 2014 Oct 26. No abstract available.

18.

Regulatory Issues in Pro Advertising: A Review of the Ddmac/Opdp Letters From 1998 To 2013 To Identify Pro Claims Violations and Examine Their Evolution Over Time.

Acquadro C, Regnault A, Arnould B.

Value Health. 2014 Nov;17(7):A517. doi: 10.1016/j.jval.2014.08.1604. Epub 2014 Oct 26. No abstract available.

19.

Pooling of cross-cultural PRO data in multinational clinical trials: how much can poor measurement affect statistical power?

Regnault A, Hamel JF, Patrick DL.

Qual Life Res. 2015 Feb;24(2):273-7. doi: 10.1007/s11136-014-0765-x. Epub 2014 Sep 5.

PMID:
25190565
20.

Using quantitative methods within the Universalist model framework to explore the cross-cultural equivalence of patient-reported outcome instruments.

Regnault A, Herdman M.

Qual Life Res. 2015 Jan;24(1):115-24. doi: 10.1007/s11136-014-0722-8. Epub 2014 Jun 4.

PMID:
24894383

Supplemental Content

Loading ...
Support Center